Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

cardiologist Peter J. Fitzgerald, MD, PhD, HeartBeam

Cardiac technology startup names cardiologist Peter Fitzgerald its chief medical officer

Fitzgerald, a leading figure in interventional cardiology, praised the company's potential to improve patient outcomes and quality of life. 

October 12, 2022
Example of QFR technology, which uses a rotation of the C-arm around the patient to create a 3D model and a color coded map showing the FFR values and drops in blood flow.

FFR-angiography guided lesion selection for PCI improves two-year outcomes in TCT late-breaker

Two-year outcomes of a QFR-guided vessel and lesion selection strategy showed that the benefits of QFR guidance continued to accrue over time compared with standard angiography guidance in patients undergoing PCI.

September 27, 2022
High-risk percutaneous coronary intervention (PCI) with an Impella heart pump is associated with better outcomes, including a significantly higher survival rate, than high-risk PCI with an intra-aortic balloon pump (IABP), according to new findings published in the American Journal of Cardiology. Impella Heart Pump Abiomed RECOVER IV RCT cardiogenic shock

Regulatory Roundup: FDA clears AI model for RV/LV ratios, approves calcium-blocking TAVR valve and much more

Read our review of some of the biggest FDA-related stories that have hit cardiology in the last month, including news from Viz.ai, Edwards Lifesciences, Abiomed and Medtronic. 

September 23, 2022
TCT 2022 Robert Califf FDA Commissioner. Robert Califf, MD, the 25th commissioner of the U.S. Food and Drug Administration (FDA), delivered the keynote address in front of a packed room of cardiologists, surgeons and medical device manufacturers. A cardiologist himself—and an adjunct professor of cardiology at the Duke University School of Medicine. He spoke on innovation in cardiology and the need to stop misinformation..

FDA Commissioner Robert Califf delivers fiery speech on innovation, healthcare disparities and misinformation at TCT 2022

“The United States is essentially inventing the technology and then the rest of the world is figuring out how to use it better,” he said.

September 18, 2022
The Medtronic CoreValve Evolut and the Edwards Lifesciences Sapien 3 TAVR valves.

TAVR's success has changed how cardiologists and surgeons view aortic valve replacement

The standard-of-care thinking on TAVR has shifted from getting a valve implanted and managing immediate complications to looking decades down the road and considering the patient's long-term health. 

August 31, 2022
ESC Congress 2022 European Society of Cardiology. 6 key sessions from ESC Congress 2022: TAVR mortality, AI vs. sonographers, radial vs. femoral access and more

6 key sessions from ESC Congress 2022: TAVR mortality, AI vs. sonographers, radial vs. femoral access and more

ESC Congress 2022, the annual meeting of the European Society of Cardiology, was jam-packed with eye-opening new research from many of the leading voices in cardiovascular and vascular medicine. These six sessions were just some of the weekend's many highlights. 

August 29, 2022
Echo:Prio represents the latest addition to Dyad Medical's cloud-based Libby platform. Image courtesy of Dyad Medical.

Regulatory Roundup: FDA approves new-look self-expanding stent, clears 2 advanced AI models

The FDA has had a busy month, overseeing the recall of nearly 88,000 implantable cardiac devices, juggling the continued rise of monkeypox cases in the United States and maintaining an active Breakthrough Devices program. This rundown covers some of the agency's biggest moves during that time. 

August 24, 2022

Boston Scientific acquires startup behind new FDA-cleared embolization technology

The new hydrogel material was designed to immediately conform to the patient's body and create a barrier.

August 15, 2022

Around the web

The recall includes specific lots of five different medical devices used to treat stroke and other neurovascular diseases.

The agency is urging healthcare providers to transition away from these devices and seek out alternatives. It is even working with other manufacturers to try and get similar products on the market as quickly as possible. 

Jeffrey Kuvin, MD, one of the leading voices behind efforts to create a new Board of Cardiovascular Medicine, spoke with Cardiovascular Business about where things stand today.

Trimed Popup
Trimed Popup